Skip to main content
Clinical Trials/CTRI/2020/06/025559
CTRI/2020/06/025559Completed未知

A single centre, prospective, randomized, open labelled clinical study to evaluate the effectiveness of Siddha herbal formulation, Vipro, in uncomplicated respiratory infections

Buy Happy Marketing LLP0 sites60 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
未知
Status
Completed
Enrollment
60

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1. Having uncomplicated respiratory infections, at least for less than 5 days, diagnosed with clinical symptoms and signs of fever, myalgia, rhinitis, sore throat, throat pain, cough, expectoration and head ache
  • 2. Consenting to participate in the study and sign the informed consent

Exclusion Criteria

  • 1. Patients with uncontrolled co-morbid conditions like Diabetes mellitus, Hypertension and Bronchial asthma
  • 2. Patients with Lower respiratory tract infections, Chronic Bronchitis, Chronic obstructive air way problems
  • 3. Patients with significant Cardiovascular, Neurological , Psychiatric, Gastro intestinal and other system infections or disorders and malignancies
  • 4. Hypersensitivity to the herbal ingredients in the formulations and other medications prescribed in the study
  • 5. Pregnant and feeding mothers
  • 6. When the patients are interviewed for selection, all those patients who come under the testing criteria for COVID-19 as per ICMR guidelines will be tested for COVID â?? 19 and if they are found to be positive, they will be excluded from participating in the study.

Investigators

Similar Trials

Evaluation of Siddha herbal formulation,... | Clinical Trial